

**2025  
NFCR**

# GLOBAL SUMMIT AND AWARD CEREMONIES



FOR **CANCER RESEARCH &  
ENTREPRENEURSHIP**



**FRIDAY  
OCTOBER 24  
2025**



**WASHINGTON, D.C.**  
**THE NATIONAL PRESS CLUB**  
529 14TH ST NW, WASHINGTON, D.C. 20045

**CO-HOSTED BY:**



**National Foundation  
for Cancer Research**  
*We Make Cures Possible*



**AIM+HI**  
ACCELERATOR FUND

**WE DRIVE CURES  
FORWARD**



National Foundation  
for Cancer Research  
We Make Cures Possible

JOIN THE GLOBAL EFFORT TO CURE CANCER:

# YOUR PARTNERSHIP CAN MAKE A LIFE-SAVING IMPACT

The **National Foundation for Cancer Research (NFCR)** is at the forefront of a global network dedicated to curing cancer. Since 1973, NFCR has provided \$420 million in funding for cutting-edge cancer research, prevention, and public education. By collaborating with leading organizations and top scientists worldwide, NFCR drives game-changing discoveries in detection, treatments, and prevention. Our focus on “high-risk, high-reward” research, often overlooked by other major funders, has led to life-saving breakthroughs that benefit patients today.

Your support can accelerate the next big breakthrough. Partner with NFCR and make a direct impact on the future of cancer research. Together, we can transform innovative ideas into life-saving solutions and bring us closer to a cure. Join our mission and be part of the global effort to end cancer.

**COMMIT TO ADVANCING CANCER RESEARCH  
AND HELP SHAPE THE FUTURE OF CANCER CARE.**



NFCR.org

# PART I: Precision Medicine & AI in Oncology

8:30 AM – 8:40 AM

## WELCOME AND OPENING REMARKS



**Sujuan Ba, Ph.D.**

*CEO of NFCR & Co-Founder of AIM-HI*



**Webster K. Cavenee, Ph.D.**

*Chair of NFCR Scientific Advisory Board;  
Distinguished Professor Emeritus,  
University of California San Diego*

8:40 AM – 9:10 AM

## KEYNOTE ADDRESS



**Monica Bertagnolli, M.D.**

*17th Director of the National Institutes of Health;  
Senior Fellow in Healthcare Policy,  
Harvard Kennedy School of Government*

# PART I: Precision Medicine & AI in Oncology

9:10 AM – 10:10 AM

## SESSION I

### AI IN CANCER RESEARCH – FROM DISCOVERY TO SOCIETAL IMPACT



#### MODERATOR

**Kornelia Polyak, M.D., Ph.D.**

*Professor of Medicine,  
Dana-Farber Cancer Institute*



#### PANELIST

**Alexander Anderson, Ph.D.**

*Chair of Integrated  
Mathematical Oncology,  
Moffitt Cancer Center*



#### PANELIST

**Jeffrey Golden, M.D.**

*Director of the Burns and  
Allen Research Institute,  
Cedars-Sinai Medical Center*



#### PANELIST

**Bruce Johnson, M.D.**

*Institute Physician Emeritus,  
Dana-Farber Cancer Institute;  
Professor of Medicine Emeritus,  
Harvard Medical School*



#### PANELIST

**Dan Theodorescu, M.D., Ph.D.**

*Nancy C. and Craig M. Berge Director,  
University of Arizona Cancer Center*

---

10:10 AM – 10:30 AM COFFEE BREAK

---

# PART I: Precision Medicine & AI in Oncology

10:30 AM – 11:30 AM

## SESSION II

### AI IN CANCER DIAGNOSIS AND MANAGEMENT



#### MODERATOR

**Jennifer Grandis, M.D.**

*Professor of Otolaryngology –  
Head and Neck Surgery, University  
of California, San Francisco*



#### PANELIST

**Maximilian Diehn, M.D., Ph.D.**

*Professor of Radiation  
Oncology, Stanford University*



#### PANELIST

**Ruijiang Li, Ph.D.**

*Associate Professor of  
Radiation Oncology,  
Stanford University*



#### PANELIST

**Paul Macklin, Ph.D.**

*Professor, Intelligent Systems  
Engineering, Indiana University*



#### PANELIST

**Kun-Hsing Yu, M.D., Ph.D.**

*Associate Professor,  
Department of Biomedical  
Informatics, Harvard University*



# PART I: Precision Medicine & AI in Oncology

11:30 AM – 12:30 PM

## SESSION III

### AI IN EARLY DETECTION AND PREVENTION



#### MODERATOR

**Nathan Lear**

*Head, Advanced Medical Analytics, AstraZeneca*



#### PANELIST

**Ludmil Alexandrov, Ph.D.**

*Professor, Department of Bioengineering & Department of Cellular and Molecular Medicine, UC San Diego*



#### PANELIST

**Lisa Coussens, Ph.D.**

*Director, Knight Cancer Institute; Professor & Chair, Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University*



#### PANELIST

**Elana Fertig, Ph.D.**

*Director of Institute for Genome Sciences, University of Maryland School of Medicine*



#### PANELIST

**Sam Hanash, M.D., Ph.D.**

*Director, Department of Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer, The University of Texas MD Anderson Cancer Center*

---

12:30 PM LUNCH

---

# **PART II: AIM-HI Oncology Leadership & Entrepreneurship Forum**

**1:00 PM**

## **WELCOMING REMARKS**



### **MASTER OF CEREMONIES**

**Patty Obermaier, MBA**  
*Founder & CEO of Resigility*

**1:05 PM – 1:20 PM**

## **FROM IDEA TO IND: LEGAL BUILDING BLOCKS FOR A BIOTECH STARTUP**



**Catherine Pan-Giordano**  
*Partner & Corporate Group Head,  
New York Office, Dorsey & Whitney*

# PART II: AIM-HI Oncology Leadership & Entrepreneurship Forum

1:20 PM – 1:30 PM

## AIM-HI VENTURE COMPETITION AWARDS CEREMONY

### PRESENTING THE AWARD CERTIFICATES TO THE WINNERS



**Pamela Garzone, Ph.D.**

*Co-Chair of the Venture Competition  
Selection and Investment Committees; Chief  
Development Officer of Anixa Biosciences*



**Dimitra Georganopoulou, Ph.D.**

*Co-Chair of the Venture Competition Investment  
Committee; General Partner of Qral Ventures*

### AWARD WINNERS



**Michelle Arkin, Ph.D.**

*Co-Founder  
ResNovas Therapeutics*



**Kirsten Flowers, M.B.A.**

*CEO & Co-Founder  
Chiara Biosciences*

**ResNovas  
Therapeutics**

 **CHIARA**  
BIOSCIENCES



# PART II: AIM-HI Oncology Leadership & Entrepreneurship Forum

1:30 PM – 2:40 PM

## EMERGING ONCOLOGY COMPANIES SHOWCASE



**MODERATOR**

**Ronald DePinho, M.D.**

*Professor, Department of Cancer  
Biology, Division of Discovery  
Science, The University of Texas  
MD Anderson Cancer Center*



**PRESENTER**

**Michelle Arkin, Ph.D.**

*Co-Founder  
ResNovas Therapeutics*



**PRESENTER**

**Kirsten Flowers, M.B.A.**

*CEO & Co-Founder  
Chiara Biosciences*



**PRESENTER**

**Rick Fultz**

*CEO & Board Member  
Acurion*



**PRESENTER**

**Chih-Kao Hu, Ph.D.**

*Interim CEO & Director  
Window Therapeutics*

---

**2:40 PM – 3:00 PM COFFEE BREAK**

---

# PART II: AIM-HI Oncology Leadership & Entrepreneurship Forum

3:00 PM – 4:00 PM

## INVESTOR PERSPECTIVE FOR EARLY-STAGE ONCOLOGY COMPANIES



### **MODERATOR**

**Matt Tremblay, Ph.D.**

*Chair of the AIM-HI Board of Directors;  
CEO of Blackbird Laboratories*



### **PANELIST**

**Mey Boukenna, M.D., Ph.D.**

*Partner, Life Sciences &  
Healthcare Investments,  
Pags Group*



### **PANELIST**

**Cynthia Cai, Ph.D., MBA**

*Venture Partner,  
Viva BioInnovator*



### **PANELIST**

**Dimitra Georganopoulou, Ph.D.**

*General Partner,  
Qral Ventures*



### **PANELIST**

**Jimmy Lu, J.D., MBA**

*Co-Founder & Managing Director,  
Eos BioInnovation*

---

**4:00 PM – 6:00 PM INTERMISSION**

---

# PART III: Dinner & Szent-Györgyi Prize Award Ceremony



6:00 PM – 6:55 PM

**RECEPTION**

7:00 PM – 9:00 PM

**SZENT-GYÖRGYI PRIZE CEREMONY**



**EMCEE**

**Kristen Berset-Harris**

*NFCR Community Ambassador  
& Cancer Survivor*

**MOMENT OF SILENCE  
IN HONOR OF  
CANCER VICTIMS**



**OPENING REMARKS**

**Sujuan Ba, Ph.D., CEO of NFCR,**

*Co-Founder of AIM-HI, & Co-Chair of 2025  
Szent-Györgyi Prize Selection Committee*

**INTRODUCTION BY 2024 SZENT-GYÖRGYI PRIZE WINNER**

**AWARD PRESENTATION TO THE 2025 SZENT-GYÖRGYI PRIZE WINNER**

**2025 SZENT-GYÖRGYI PRIZE WINNER AWARD ADDRESS**



**AWARD PRESENTATION BY  
2024 SZENT-GYÖRGYI PRIZE WINNER:**

**Dennis J. Slamon, M.D., Ph.D.**

*Professor of Medicine, Director of Clinical and  
Translational Research, Jonsson Comprehensive Cancer  
Center, David Geffen School of Medicine at UCLA*



**2025 SZENT-GYÖRGYI PRIZE WINNER:**

**Tony Hunter, Ph.D.**

*American Cancer Society Professor,  
Salk Institute for Biological Studies*

# PART III: Dinner & Szent-Györgyi Prize Award Ceremony

## PRESENTATION OF THE 2025 SZENT-GYÖRGYI PRIZE WINNER



# THE SZENT-GYÖRGYI

PRIZE FOR PROGRESS  
IN CANCER RESEARCH



**Tony Hunter, Ph.D.**

*American Cancer Society Professor,  
Salk Institute for Biological Studies*

In 1979, while studying how certain cancer-causing viruses alter cells, Dr. Hunter uncovered a previously unknown cellular process: tyrosine phosphorylation. This mechanism, which involves the addition of phosphate groups to tyrosine residues on proteins, revealed how cells transmit growth signals — a process central to cell division and communication. Crucially, he showed that when this signaling pathway goes awry, it can drive the unchecked cell growth that defines cancer.

At the time, no one even knew this kind of signaling occurred in cells. Dr. Hunter's insight opened up an entirely new field of study: tyrosine kinase signaling. His work provided the molecular blueprint for targeted cancer therapies, enabling the development of more than 50 FDA-approved tyrosine kinase inhibitors (TKIs) that precisely block cancer-driving signals. These therapies have transformed outcomes for patients with leukemia, lung cancer, gastrointestinal tumors, and many other malignancies.

One of the first and most well-known therapies to emerge from this breakthrough was Gleevec, which revolutionized treatment for chronic myeloid leukemia and has saved hundreds of thousands of lives worldwide.

"Dr. Hunter's foundational discovery has changed how we understand and treat cancer," said Dr. Dennis Slamon, Chair of the 2025 Prize Committee. "His work led directly to life-saving targeted therapies used every day."

NFCR President and CEO Dr. Sujuan Ba added, "Dr. Hunter's contribution opened a new field that continues to drive breakthroughs in both understanding and treating cancer. We are proud to honor him and invite the world to celebrate his milestone discoveries with us."

Reflecting on the honor, Dr. Hunter said, "I am deeply honored to receive this award. It's a tribute to everyone working to turn science into better treatments for patients."



# PART III: Dinner & Szent-Györgyi Prize Award Ceremony

8:15 PM

## PANEL DISCUSSION LIVE FROM PRESS CLUB



**PANELIST**

**Anna D. Barker, Ph.D.**  
*Chief Strategy Officer,  
Ellison Medical Institute*



**PANELIST**

**Thomas Clark**  
*Cancer Patient Caregiver &  
Cancer Research Supporter*



**PANELIST**

**Alison Dziarmaga, Ph.D.**  
*Vice President, US Franchise  
Head, Breast Cancer, AstraZeneca*



**PANELIST**

**Jennifer Grandis, M.D.**  
*Professor of Otolaryngology –  
Head and Neck Surgery, University  
of California, San Francisco*



**PANELIST**

**Tony Hunter, Ph.D.**  
*American Cancer Society  
Professor, Salk Institute  
for Biological Studies*

8:45 PM

## CLOSING REMARKS



**Kristen Berset-Harris**  
*NFCR Community Ambassador & Cancer Survivor*



# About the AIM-HI Venture Competition

The AIM-HI Accelerator Fund, in collaboration with the National Foundation for Cancer Research, launched the AIM-HI Venture Competition in 2020. This one-of-a-kind annual competition provides early-stage oncology companies worldwide with lifeline seed funding, critical coaching, and continuous access to our global network.

AIM-HI has established a rigorous and unparalleled three-part review and due diligence process to select the most deserving candidates. AIM-HI thanks the members of the Selection, Judging, and Investment Committees for their dedication to the success of the 2025 Competition.

***We are deeply grateful to Faegre Drinker Biddle & Reath LLP, Cooley LLP, and Qral Group for their pro bono services and critically-needed support.***

## 2025 AIM-HI VENTURE COMPETITION COMMITTEE

(ALPHABETICAL ORDER)

**Anna D. Barker, Ph.D.**

*Chief Strategy Officer,  
Ellison Medical Institute*

**Mey Boukenna, M.D., Ph.D.**

*Vice President, Pags Group*

**Tom Brennan**

*Former Venture Partner, Arch Venture Partners*

**Rita Brogley, MBA**

*Managing Partner, Rebar Advisors,  
and Trinity Health Board*

**Webster K. Cavenee, Ph.D.**

*Distinguished Professor Emeritus,  
University of California San Diego*

**Aleksandra Filipovic, M.D., Ph.D.**

*Head of Oncology, PureTech Health*

**Pamela Garzone, Ph.D.**

*Chief Development Officer, Anixa Biosciences*

**Dimitra Georganopoulou, Ph.D.**

*General Partner, Qral Ventures*

**Colin Hill**

*Co-Founder & CEO, Aitia Bio*

**Raju Kucherlapati, Ph.D.**

*Paul C. Cabot Professor of Genetics and Professor  
of Medicine, Harvard Medical School*

**Scott Lippman, M.D.**

*Distinguished Professor of Medicine & Associate Vice  
Chancellor for Cancer Research, UC San Diego Health*

**Jimmy Lu, J.D., MBA**

*Co-Founder and Managing Director, Eos BioInnovation*

**Eva Martin, M.D.**

*Senior Director, Alliance and Asset  
Management, Roche Pharma Partnering*

**Eddie Martucci, Ph.D.**

*Co-Founder & Chair of the Board, Akili Interactive*

**Bonnie Weiss McLeod, Ph.D.**

*Of Counsel, Cooley LLP*

**Gregory W. Mitchell, Ph.D.**

*Partner, Faegre Drinker Biddle & Reath LLP*

**Drew Pardoll, M.D., Ph.D.**

*Director, Bloomberg-Kimmel Institute for  
Cancer Immunotherapy, Johns Hopkins  
University School of Medicine*

**Kornelia Polyak, M.D., Ph.D.**

*Professor of Medicine, Dana-Farber Cancer Institute*

**Jacob Rayyan, Ph.D.**

*Venture Associate, Cancer Fund*

**Michael Salgaller, Ph.D.**

*Supervisory Invention Development &  
Marketing Specialist, National Institutes  
of Health/National Cancer Institute*

**Thea Tlsty, Ph.D.**

*Professor, Department of Pathology and Director  
of the Center for Translational Research in  
the Molecular Genetics of Cancer, UCSF*

**Hai Yan, Ph.D.**

*Research Director, Institute of Molecular and  
Cell Biology, The Agency for Science, Technology  
and Research (A\*Star) Singapore*

**Mengsu (Michael) Yang, Ph.D.**

*Senior Vice-President (Innovation and  
Enterprise), City University of Hong Kong*

**Wai-Kwan Alfred Yung, M.D.**

*Professor, Department of Neuro-Oncology,  
University of Texas, MD Anderson Cancer Center*

# About the AIM-HI Venture Competition

## PREVIOUS WOMEN'S VENTURE COMPETITION WINNERS



**Nabanita Nawar, Ph.D.**  
**2024 First Prize Winner**

*Co-Founder & CEO,  
HDAX Therapeutics*



**Sarah Hein, Ph.D.**  
**2023 First Prize Winner**

*Co-Founder & CEO,  
March Biosciences*



**Johanna Webb**  
**2022 First Prize Winner**

*President & CEO,  
RiverWalk Therapeutics*



**María Varela**  
**2021 First Prize Winner**

*CEO,  
ARDAN PHARMA*



**Manijeh Goldberg, Ph.D.**  
**2020 First Prize Winner**

*CEO,  
Privo Technologies*



# About the AIM-HI Beacon Award for Women Leaders in Oncology

The AIM-HI Beacon Award for Women Leaders in Oncology was established in 2022 by the AIM-HI Accelerator Fund and sponsored by the National Foundation for Cancer Research (NFCR). This award recognizes outstanding women pioneers in all sectors of the health and life sciences industry who have made a significant impact on advancing cancer treatment, detection, and diagnosis for patients worldwide through the development and commercialization of novel technologies, advocacy, and/or implementation of public policy.

## PREVIOUS AIM-HI BEACON AWARD WINNERS



**Margaret Foti, Ph.D., M.D. (hc)**

**2024 Winner**

*CEO,  
American Association for Cancer Research*



**Monica M. Bertagnolli, M.D.**

**2023 Winner**

*Director,  
National Cancer Institute*



**Anna D. Barker, Ph.D.**

**2022 Winner**

*Chief Strategy Officer,  
Ellison Institute for Transformative Medicine;  
Distinguished Visiting Fellow, Complex, Adaptive  
Systems, Arizona State University Biosciences*

*(Affiliations at the time of the Award announcement)*



# About the Szent-Györgyi Prize for Progress in Cancer Research



**ALBERT SZENT-GYÖRGYI, M.D., PH.D.**  
*Co-Founder, National Foundation for Cancer Research  
1937 Nobel Laureate in Physiology or Medicine*

---

***“Discovery is seeing what everybody else has seen,  
and thinking what nobody else has thought.”***

---

The National Foundation for Cancer Research is proud to present the Szent-Györgyi Prize for Progress in Cancer Research to honor outstanding scientists whose seminal discovery or pioneering body of work has contributed to cancer prevention, diagnosis, or treatment and has had a lasting impact on understanding cancer, holding the promise of improving or saving the lives of cancer patients.

This annual prize is named in memory of Dr. Albert Szent-Györgyi, who was a pioneer, and, like many other explorers, he challenged the conventional thinking of the day to pursue his novel and promising ideas. After winning the Nobel Prize for his study on vitamin C and cell respiration, Dr. Szent-Györgyi set his sights on finding a way to defeat cancer.

Beyond his laboratory, Dr. Szent-Györgyi was a leading advocate for developing resources to provide scientists with the financial support necessary to pursue novel cancer research ideas. In 1973, he changed the face of cancer research funding by co-founding NFCR with entrepreneur Franklin C. Salisbury. Since then, NFCR has provided \$420 million in support of cancer research and prevention education programs.

The Szent-Györgyi Prize serves to stimulate continued investment in pioneering research that will produce scientific breakthroughs. It intends to deepen the understanding of the underlying basis of cancer and the translation of this knowledge to improve the lives of cancer patients.

By calling attention annually to achievements in this area, it is the goal of the Szent-Györgyi Prize to heighten awareness of the research and the discovery that leads to new cancer treatments and cancer cures. The Prize also promotes public awareness of the importance of basic cancer research and the need to accelerate the translation of these research discoveries into new cancer treatments.

# About the Szent-Györgyi Prize Selection Committee



The Szent-Györgyi Prize Selection Committee has been established to advise and consult with the National Foundation for Cancer Research on each year's pool of Prize nominees.

Nominations are reviewed and evaluated based on the following criteria:

- A seminal discovery or pioneering body of work that has contributed to cancer prevention, diagnosis, or treatment.
- Has had a lasting impact on understanding cancer, holding the promise of improving or saving the lives of cancer patients.

## 2025 SZENT-GYÖRGYI PRIZE SELECTION COMMITTEE MEMBERS

(ALPHABETICAL ORDER)

**CHAIR:** Dennis J. Slamon, M.D., Ph.D., *University of California Los Angeles (2024 Szent-Györgyi Prize Winner)*

**CO-CHAIR:** Sujuan Ba, Ph.D., *National Foundation for Cancer Research*

Steve Baylin, M.D., *Johns Hopkins University*

Michele Carbone, M.D., Ph.D., *University of Hawaii Cancer Center*

Webster K. Cavenee, Ph.D., *University of California San Diego (2007 Szent-Györgyi Prize Winner)*

Ray DuBois, M.D., Ph.D., *Hollings Cancer Center, Medical University of South Carolina*

Benita Katzenellenbogen, Ph.D., *University of Illinois Urbana-Champaign*

Mary-Claire King, Ph.D., *University of Washington School of Medicine (2016 Szent-Györgyi Prize Winner)*

Karen Knudsen, Ph.D., *Parker Institute for Cancer Immunotherapy*

Raju Kucherlapati, Ph.D., *Harvard Medical School*

Doug Lowy, M.D., *National Cancer Institute (2018 Szent-Györgyi Prize Winner)*

Funmi Olopade, M.D., *The University of Chicago*

Dan Theodorescu, M.D., Ph.D., *The University of Arizona Cancer Center*

---

*The National Foundation for Cancer Research thanks the members of the Committee for their dedication to the success of the 2025 Szent-Györgyi Prize for Progress in Cancer Research*

---



# Previous Szent-Györgyi Prize Winners



**Dennis J. Slamon, M.D., Ph.D.**  
2024 Winner  
*University of California,  
Los Angeles*



**Isaac P. Witz, Ph.D.**  
2023 Winner  
*Tel Aviv University*



**Rakesh K. Jain, Ph.D.**  
2022 Winner  
*Harvard Medical School &  
Massachusetts General Hospital*



**Mark M. Davis, Ph.D.**  
2021 Co-Winner  
*Stanford University School  
of Medicine*



**Tak W. Mak, Ph.D.**  
2021 Co-Winner  
*University of Toronto; Princess  
Margaret Cancer Centre*



**Susan Band Horwitz, Ph.D.**  
2020 Winner  
*Albert Einstein College  
of Medicine, Bronx, New York*



**Steven A. Rosenberg,  
M.D., Ph.D.**  
2019 Winner  
*National Cancer Institute*



**Douglas R. Lowy, M.D.**  
2018 Co-Winner  
*National Cancer Institute*



**John T. Schiller, Ph.D.**  
2018 Co-Winner  
*National Institutes of Health*



**Michael N. Hall, Ph.D.**  
2017 Winner  
*Biozentrum of the University  
of Basel, Switzerland*



**Mary-Claire King, Ph.D.**  
2016 Winner  
*University of Washington*



**Frederick W. Alt, Ph.D.**  
2015 Winner  
*Harvard Medical School & Boston  
Children's Hospital*



**James P. Allison, Ph.D.**  
2014 Winner  
*The University of Texas,  
MD Anderson Cancer  
Center, Houston*



**Alex Matter, M.D.**  
2013 Winner  
*Agency for Science,  
Technology and Research  
(A\*STAR), Singapore*



**Zhen-Yi Wang, M.D.**  
2012 Co-Winner  
*Shanghai Jiao  
Tong University*



**Zhu Chen, M.D., Ph.D.**  
2012 Co-Winner  
*Shanghai Jiao  
Tong University*



**Beatrice Mintz, Ph.D.**  
2011 Winner  
*Fox Chase Cancer  
Center, Philadelphia*



**Peter K. Vogt, Ph.D.**  
2010 Winner  
*Scripps Research La Jolla*



**Ronald A. DePinho, M.D.**  
2009 Winner  
*The University of Texas,  
MD Anderson Cancer  
Center, Houston*



**Carlo M. Croce, M.D.**  
2008 Winner  
*The Ohio State University*



**Webster K.  
Cavenee, Ph.D.**  
2007 Winner  
*University of California,  
San Diego*



**Harold F. Dvorak, M.D.**  
2006 Winner  
*Harvard Medical School  
and Beth Israel Deaconess  
Medical Center, Boston*

## Our Generous Sponsors

### PLATINUM SPONSORS



*We are leading  
a revolution to  
transform  
cancer care.*





Help Us Bring Forth the

# Future of Biomedicine

Blackbird Labs helps catalyze Baltimore's life sciences research by supporting start-up formation and development. Our goal is to commercialize the transformational science from our local academic partners and drive impact across the ecosystem and on a national scale.

BLACKBIRDLAB.ORG | INFO@BLACKBIRDLAB.ORG



**Global law firm Dorsey & Whitney LLP  
proudly supports the NFCR and its honorees.**

We are honored to advance NFCR's mission to drive innovation, collaboration, and impact in cancer prevention, diagnosis, and treatment.



**Catherine X. Pan-Giordano**

Partner

Corporate Group Head, New York Office

[pan.catherine@dorsey.com](mailto:pan.catherine@dorsey.com)

USA

CANADA

EUROPE

ASIA



# Together, We Make Cures Possible!

## SILVER SPONSORS



## BRONZE SPONSORS

IMMUNOCORE



## PARTNER SPONSORS



## TABLE SPONSORS



## STRATEGIC PARTNERS



*This activity is supported by an Educational Grant from Gilead Sciences, Inc.*

# FUELING INNOVATION

## Support the Next Generation of Cancer Treatments

The **AIM-HI Accelerator Fund** is a key player in the global network dedicated to transforming innovative cancer discoveries into life-saving treatments. Established in 2019 with support from the National Foundation for Cancer Research, AIM-HI accelerates the development of cancer drug discoveries by investing in seed-stage oncology companies. By bridging the gap between groundbreaking research and impactful cancer therapies, AIM-HI cultivates a powerful ecosystem for early-stage companies and entrepreneurs.

Your support can fuel the next wave of cancer treatment breakthroughs. Partner with AIM-HI to advance promising innovations and bring new therapies to patients around the world.

**INVEST IN THE FUTURE  
OF CANCER TREATMENT  
AND BE PART OF THE CURE.**







National Foundation  
for Cancer Research  
We Make Cures Possible



AIM-HI  
ACCELERATOR FUND

WE DRIVE CURES  
FORWARD

## ABOUT NFCR

The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization co-founded in 1973 by Nobel Laureate Dr. Albert Szent-Györgyi and Attorney/Business Entrepreneur Franklin Salisbury, Sr. NFCR provides scientists in the lab the critical seed funding they need to make game-changing discoveries in cancer detection, treatments, and prevention and ultimately, a cure for all cancers. NFCR has distinguished itself in the cancer research sector by emphasizing “high-risk, high-impact” long-term and transformative pioneering research fields, often overlooked by other major funding sources. With the support of more than 5.7 million individual donors over the last 52 years, NFCR has provided \$420 million in funding to cancer research, prevention, and public education. NFCR-supported research has led to some of the most significant lifesaving discoveries that benefit patients today.

Tax ID #: 04-2531031  
[www.NFCR.org](http://www.NFCR.org)



## ABOUT AIM-HI

The AIM-HI Accelerator Fund (AIM-HI) was created in 2019 by the National Foundation for Cancer Research to provide oncology startups with the resources they need to drive innovative discoveries forward, out of the lab, to the clinics, and eventually to the people battling cancer. Our non-profit changes the paradigm of funding biotech startups, utilizing charitable giving to make impact investments. Our mission is to bridge the gap between research breakthroughs and clinical trials, with the ultimate goal of developing innovative cancer therapies and technologies that can save patients' lives.

Tax ID #: 82-4322538  
[www.AIM-HIaccelerator.org](http://www.AIM-HIaccelerator.org)

